Similar articles

• Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.

  Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI; TAX-327 investigators. Berthold DR, et al. Clin Cancer Res. 2008 May 1;14(9):2763-7. doi: 10.1158/1078-0432.CCR-07-0944. Clin Cancer Res. 2008. PMID: 18451243 Clinical Trial.
• Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.

  Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W. Zhang HL, et al. Urol Int. 2007;79(4):307-11. doi: 10.1159/000109714. Urol Int. 2007. PMID: 18025847
• Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.

  Van Poppel H. Van Poppel H. Can J Urol. 2005 Feb;12 Suppl 1:81-5. Can J Urol. 2005. PMID: 15780173 Review.
• [Therapy of hormone refractory prostate cancer: new standards, new trends].

  Wülfing C, Bierer S, Bögemann M, Piechota H, Hertle L. Wülfing C, et al. Aktuelle Urol. 2005 Aug;36(4):342-8. doi: 10.1055/s-2004-830209. Aktuelle Urol. 2005. PMID: 16110408 Review. German.
• Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

  Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Oudard S, et al. J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738542 Clinical Trial.